Fiera Capital Corp Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fiera Capital Corp boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 141,198 shares of the company’s stock after acquiring an additional 15,463 shares during the period. Fiera Capital Corp’s holdings in IDEXX Laboratories were worth $58,377,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the third quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the 4th quarter worth about $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after acquiring an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of IDEXX Laboratories during the third quarter valued at $37,000. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on IDXX shares. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $457.35 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The company has a market cap of $37.45 billion, a P/E ratio of 42.86, a PEG ratio of 3.47 and a beta of 1.37. The stock’s 50-day moving average is $429.67 and its 200 day moving average is $453.23. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock worth $6,161,276 over the last three months. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.